ACADIA Pharmaceuticals Valuation

Q: What is the Fair Price of ACAD * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

ACAD * (MX$509) is trading below our estimate of [[fair value]] (MX$3129.2)

Is ACAD * undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ACAD * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ACAD * (MX$509) is trading below our estimate of fair value (MX$3129.2)

Significantly Below Fair Value: ACAD * is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ACAD *?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for ACAD *. This is calculated by dividing ACAD *'s market cap by their current preferred multiple.
What is ACAD *'s n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	US$3.83b

ACAD * key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	6.4x
Enterprise Value/EBITDA	-28.3x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does ACAD *'s PS Ratio compare to its peers?

The above table shows the PS ratio for ACAD * vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	4.2x
LAB B Genomma Lab Internacional. de	1.4x	5.6%	Mex$24.3b
688363 Bloomage BioTechnology	5x	15.3%	CN¥29.0b
ALKS Alkermes	2.8x	-0.7%	US$4.2b
FOLD Amicus Therapeutics	7.6x	20.3%	US$3.5b
ACAD * ACADIA Pharmaceuticals	7x	23.7%	Mex$3.8b

Price-To-Sales vs Peers: ACAD * is good value based on its Price-To-Sales Ratio (7x) compared to the peer average (9.9x).

Price to Earnings Ratio vs Industry

How does ACAD *'s PE Ratio compare vs other companies in the Global Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	0%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	0%
	n/a	n/a	n/a

No more companies

Price-To-Sales vs Industry: ACAD * is good value based on its Price-To-Sales Ratio (7x) compared to the Global Biotechs industry average (9.6x).

Price to Sales Ratio vs Fair Ratio

What is ACAD *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ACAD * PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	7x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ACAD *'s Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.